Factors that are important to consider when selecting patients with MPN for SCT

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses factors that are important to consider when selecting patients with myeloproliferative neoplasms (MPNs) for stem cell transplantation (SCT). He emphasizes prioritizing high-risk patients and carefully determining the optimal timing for SCT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.